2025 ASCO Annual Meeting: The Show and After Show

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 to June 3, in Chicago, is poised to feature practice-changing data across various cancer types.

The Show and After Show, co-hosts Kristie L. Kahl and Andrew Svonavec offer a glimpse at some of the presentations guaranteed to spark one’s curiosity, spur debate, and enhance the field even further, highlighting key areas of anticipated interest for oncology providers.

Gastrointestinal Cancers (GI): Early buzz suggests significant presentations in GI malignancies. Buzz on social media has indicated the potential for immunotherapy to move into the first-line setting, possibly establishing new standards of care. Oncologists should closely monitor these sessions for data that could dramatically alter treatment algorithms for GI cancers.

Antibody-Drug Conjugates (ADCs): ADCs are expected to be a prominent topic at this year's meeting, with notable developments across lung, breast, and bladder cancers. The innovation in this therapeutic class will likely be showcased, emphasizing the growing potential of ADCs in treating a wide range of malignancies.

Lung Cancer: The lung cancer treatment landscape continues to evolve rapidly, with ADCs, KRASG12C inhibitors, and tyrosine kinase inhibitors (TKIs) taking center stage. The synergy and novel combinations of these agents hold promise for extending and improving the lives of patients with lung cancer. Attendees should anticipate data that could redefine treatment paradigms.

Plenary Session Highlights: The plenary session is generating considerable excitement, particularly regarding late-breaking abstract LBA4. This session will likely feature highly anticipated data, as providers await the comparison of Keynote-689 (NCT03765918) findings from the 2025 AACR Annual Meeting with the NIVO-Post-Op (NCT03576417) data. This comparison may aid in understanding potential shifts in treatment strategies.

Key Immunotherapy Agents: Familiar immunotherapy agents continue to play a crucial role in cancer treatment. Pembrolizumab, nivolumab, bevacizumab, atezolizumab, and ipilimumab are highlighted as top products to watch, with new data expected to further refine their integration into various treatment strategies.

Giants of Cancer Care: The annual Giants of Cancer Care ceremony will take place on Thursday, May 29, at the Adler Planetarium. This event recognizes individuals who have made significant contributions to the field of oncology.

GO to PER in Chicago: PER is excited to host a wide range of continuing medical education, in-person and virtual satellite symposia. The symposia will deliver exceptional content and practical education with sessions focused on breast, lung, prostate, hematologic cancers, and many more.

The ASCO 2025 Annual Meeting promises to be a pivotal event, featuring potential breakthroughs and evolving treatment paradigms across multiple cancer types.